Evidence map›Paper›PMID 34128116›Full record

ArticleVirchows Archiv : an international journal of pathology2022

EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.

Antic Tatjana, Melissa Y Tjota, Peter H O'Donnell, Scott E Eggener, Piyush K Agarwal, Rishikesh Haridas, Jeremy Segal, Peng Wang

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Combined RET and MEK Inhibition as a Treatment forJTO clinical and research reports · 2024
    Article
  3. Review
  4. Detection ofFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Antic TatjanaDepartment of Pathology, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA. Tatjana.Antic@uchospitals.edu.
Melissa Y TjotaDepartment of Pathology, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0002-5869-3175
Peter H O'DonnellDepartment of Hematology and Oncology, The University of Chicago, Chicago, IL, USA.
Scott E EggenerSection of Urology, The University of Chicago, Chicago, USA.
Piyush K AgarwalSection of Urology, The University of Chicago, Chicago, USA.
Rishikesh HaridasDepartment of Pathology, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA.
Jeremy SegalDepartment of Pathology, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA.
Peng WangDepartment of Pathology, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA.
University of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A subset of renal cell carcinomas harbor gene fusions, and we report the first case of an EZR-ROS1 fusion in renal cell carcinoma. A 47-year-old female presented with hematuria and a mass involving the renal pelvis. Renal biopsy revealed a tumor with solid and tubular architecture that was diffusely positive for PAX8, CK7, and vimentin; retained expression of INI1; focally positive for P504S; and negative for GATA3 and TFE3. Partial nephrectomy was performed, and histologically, the tumor had solid and tubular architecture with mucin-like content within tubules. The nuclei corresponded to WHO/ISUP grade 2 and 3. The morphology was neither specific nor diagnostic, and a final diagnosis of unclassified renal cell carcinoma with solid and tubular architecture was rendered. Molecular sequencing revealed an EZR-ROS1 fusion: a fusion that has never been reported in renal cell carcinoma. Recognition of this fusion is of significance if the tumor becomes metastatic as treatment with crizotinib may be considered.

Indexed as

Carcinoma, Renal CellCarcinoma, Transitional CellKidney NeoplasmsUrinary Bladder NeoplasmsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorFemaleGene FusionHumansMiddle AgedProtein-Tyrosine KinasesProto-Oncogene ProteinsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, humanDNA sequencingEZR-ROS1 fusionKidneyRenal massRNA sequencing

Identifiers

PMID34128116
OpenAlexW3166909579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.